1 Department of Molecular Medicine, University of Pavia, Pavia, Italy.
2 Biotechnology Research Laboratories, IRCCS San Matteo Foundation, Pavia, Italy.
3 Unit of Microscopic and Ultrastructural Anatomy, Department of Medicine, University Campus Bio-Medico, Rome, Italy
4 Department of Biomedical and Neuromotorial Sciences, Alma Mater University, Bologna, Italy.
5 Department of Biomedical Engineering, Tufts University, Medford, MA, USA
Received: August 15, 2018
Accepted: October 23, 2018
Mediterr J Hematol Infect Dis 2018, 10(1): e2018068 DOI 10.4084/MJHID.2018.068
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Primary Myelofibrosis (PMF), megakaryocyte dysplasia/hyperplasia
determines the release of inflammatory cytokines that, in turn,
stimulate stromal cells and induce bone marrow fibrosis. The pathogenic
mechanism and the cells responsible for progression to bone marrow
fibrosis in PMF are not completely understood. This review article aims
to provide an overview of the crucial role of megakaryocytes in
myelofibrosis by discussing the role and the altered secretion of
megakaryocyte-derived soluble factors, enzymes and extracellular
matrices that are known to induce bone marrow fibrosis.
Recent evidence has shown that the amount of BM reticulin often exhibits no correlation to disease severity, while the presence of collagen fibres is often associated with more severe disease and a poorer prognosis. The exact pathogenesis of BM fibrosis is not fully understood. Aberrant tyrosine kinase signaling is a common hallmark in MPNs and has been shown to represent a key driver of the disease. The three currently recognized driver mutations in PMF are JAK2 (Janus kinase 2; located on chromosome 9p24), CALR (calreticulin; located on chromosome 19p13.2), and MPL (myeloproliferative leukemia virus oncogene; located on chromosome 1p34). The JAK2 V617F substitution of a valine for a phenylalanine destabilizes the JH2 domain of JAK2 and causes loss of the auto-inhibitory activity of this domain. The most common MPL mutations, W515L (tryptophan-to-leucine substitution) and W515K (tryptophan-to-lysine substitution), cause both cytokine-independent growth and hyper-TPO sensitivity. JAK2V617F and MPL 515 mutations are present in about 50% and 5% of PMF cases respectively, resulting in permanent activation of the JAK/STAT signaling pathways and conferring in vitro altered response of mutated clones to thrombopoietin (TPO) and other cytokines.[3,5] In 2013 type 1 mutations (52-bp deletion) and type 2 mutations (5-bp insertion) were discovered in the Calreticulin gene. These mutations determine a constitutive activation of the MPL receptor through abnormal interaction with mutated calreticulin.[6,7]
Of the myeloproliferative disorders, PMF has the worst overall prognosis and morbidity. Despite many significant advances in the treatment of this disease, many aspects of its origin and progression remain poorly understood. While recent understanding, on the pathogenic mechanisms in hematopoietic stem cells (HSCs), provides an explanation for myeloproliferation, several pieces of evidence clearly demonstrate that other processes are involved in this disease than the simple uncontrolled growth of mutant cells. In addition to BM fibrosis, the malignant stem cells exit from the BM as the disease progresses, and relocate in other hematopoietic organs, mostly the spleen and the liver. This leads to the enlargement of the spleen and liver that is characteristic of this disease, causing significant morbidity. In PMF the pathogenesis of myelofibrosis appears to be intimately linked with megakaryocyte (Mk) proliferation and differentiation. Mks have the primarily function to generate and release platelets in close proximity of BM vasculature, but they have also been shown to be involved in the control of BM homeostasis through the generation of signals that regulate HSC self-renewal and quiescence,[13,14] or differentiation of others BM cell niche, such as plasma cells or osteoblasts.
In PMF clusters of immature and necrotic Mks, surrounded by fibrotic areas in the BM, suggests that improper or premature release of their neat cargo of intracellular proteins unleash the uncontrolled and disseminated fibrotic reaction driven by BM stromal cells. Noteworthy, Mks are very rich in cytokines, growth factors, cross-linking enzymes and extracellular matrix proteins (ECM) that are known to directly cause tissue fibrosis by stimulating stromal cells to produce collagen or that physically participate to ECM remodeling and BM scarring. Thus, here we will review what is known about the potential contribution of Mks to the onset and progression of BM fibrosis.
Megakaryocyte cargo in physiological thrombopoiesis
Megakaryopoiesis is mainly driven by TPO, although this cytokine may be dispensable for terminal megakaryocyte maturation in vitro. During the early stages of their differentiation, Mks become polyploid through repeated DNA replication and endomitotic cycles without cytokinesis. At the end of maturation, the Mk cytoplasm becomes very specialized with the development of a complex system of membranes, called the demarcation membrane system (DMS), and three different types of granules including lysosomes, dense granules and α-granules. Proteins contained in the α-granules (specialized secretory granules) can be synthesized or endocytosed. As in other cells, the cell-specific proteins are synthesized by ribosomes on the rough endoplasmic reticulum and then packaged via the Golgi apparatus into nascent granules. Mk α-granules are the most abundant secretory organelles and contain a large variety of adhesive proteins, such as β-thromboglobulin, CXCL4 (platelet factor 4, PF4), thrombospondin, fibronectin (FN), von Willebrand factor (vWF) and P-selectin. In addition, anti-angiogenic factors, endostatin and angiostatin, and pro-angiogenic factors such as VEGF and SDF-1α, are involved in the regulation of lymphatic system development and vascular integrity promoted by α-granule.[23,24] Mk α-granules contain additional growth factors for vascular repair, such as Platelet Derived Growth Factor (PDGF), Transforming Growth Factor-β1 (TGFβ1), Epidermal Growth Factor (EGF) and Insulin Growth Factor (IGF). Furthermore, members of the metalloproteinases (MMP) and tissue inhibitors of metalloproteinases (TIMP) family, which are important factors in angiogenesis and tissue remodeling, are also stored in Mk cytoplasm. In addition, these granules have been shown to contain several plasma proteins, such as fibrinogen, Factor V, albumin and immunoglobulin, which are not synthesized by the cell and are, therefore, endocytosed. Lastly, the pro-coagulant factors II, V, XI and XIII, high molecular weight kininogens, the anti-fibrinolytic factors plasminogen activator inhibitor-1, α2-antiplasmin and carboxypeptidase B2, anti-coagulant factors, for example, antithrombin, protein S, C1-inhibitor, TFPI and protease nexin 2 and pro-fibrinolytic proteins such as plasminogen and plasmin have been all localized in α-granules.
Differently from α-granules, secretory lysosomes contain distinct acid hydrolases, such as beta- hexosaminidase, heparanase, elastase, and cathepsin D and E. Finally, Mk dense granules store small bioactive molecules, while α-granules are predominantly protein-packed. The cargo comprises nucleotides (e.g., ADP, ATP), polyphosphates, Ca2+ and Mg2+ cations, but also neurotransmitters and hormones, such as serotonin and histamine.
How do megakaryocytes target and deliver their protein cargo within bone marrow milieu?
To this regard, Ma et al. observed that platelet stimulation with specific protease-activated receptor- 1 (PAR-1) or PAR-4 agonist resulted in the preferential release of VEGF or endostatin (anti- and pro-angiogenic factors, respectively).[24,43] More recently, a super-resolution immunofluorescence co-localization analysis of 15 platelet α-granule cargoes failed to confirm any functional co- clustering of these proteins. Moreover, Zingariello et al. demonstrated by immunoelectron microscopy that P-selectin and von Willebrand factor (vWF) are co-localized within the same intracellular α-granules in immature Mks. The two proteins, however, are not co-localized in α- granules of mature Mks after wild type mice treatment with TPO. These results suggested that P- selectin and vWF are associated in the Mk cytoplasm at early stages of maturation but that they are routed into separate anti-angiogenic or pro-angiogenic α-granule subtypes as these cells mature. Thus, the differential association of vWF and P-selectin with anti-angiogenic or pro-angiogenic factors suggest that a mechanism regulating the sequential release of different α-granule subtypes may be involved in Mk/platelet function during tissue repair. Interestingly, Mks derived from the GATA-1low mice, which harbors a hypomorphic mutation that blocks Mk maturation and displays BM fibrosis, showed reduced levels of expression of vWF and displaced P-selectin on the demarcation membrane system.
Further, the loss of alpha granules within BM Mks in a mouse model of Gray Platelet Syndrome (GPS) induced a myelofibrotic phenotype. In PMF patients, ultrastructural abnormalities and variety in Mk-granules were reported by Thiele et al. more than 25 years ago. Platelets derived from MPN patients showed several qualitative abnormalities, including decreased alpha granules and mitochondria and also alterations of the dense and tubular canalicular system. Reduced levels of ADT, ATP and serotonin content in dense granules and lower content of beta-thromboglobulin (BTG) and platelet factor 4 (PF4) in alpha granules were also described.[49,50] Thus, aberrant assembly and secretion of Mk granules represent a potential mechanism of BM fibrosis progression (Figure 1).
|Figure 1. Schematic representation of potential mechanisms for aberrant release of Mk content in bone marrow fibrosis.|
A second intriguingly hypothesis is that intracellular Mk/platelet products may be delivered in the surrounding space by extracellular vesicles (EVs). EVs are membrane-enclosed structures of varying size (50-10,000 nm) released from cells to mediate both local and distant intercellular communication. EVs of various shapes and sizes have been demonstrated in several body fluids, with substantial variation in their structure, content and function. There are three main types: exosomes (50-100 nm), microparticles (200 nm-1 µm) and apoptotic bodies. Protein, lipid and RNA components contribute to cell-cell crosstalk at a short distance, in a paracrine or endocrine manner via the bloodstream. In addition, they may transfer surface receptors from one cell to another and deliver proteins, mRNA, bioactive lipids, and even whole organelles (e.g., mitochondria) into target cells. It has been reported that two mechanisms used by target cells to integrate EVs are cell endocytosis and membrane fusion. Recent studies of EVs in the BM have shown that these vesicles serve to regulate hematopoiesis, participate in immune cell activation, and hemostasis.[54,55] Several lines of evidence suggest that EVs are involved in regulating BM function during homeostasis and in response to injury, but also that hematological malignancies such as leukemia, multiple myeloma or viral infections can exploit EVs trafficking to reinforce tumor growth, chemotherapeutic resistance, invasion and metastasis.[56,57] Platelet-derived vesicles were first identified by electron microscopy over 50 years ago, but the definition of their features and activities have only become a major focus of interest in recent years. Platelet-derived microparticles (PMPs) are released from the platelet surface and are distinguished from platelet exosomes, which are derived from endocytosis and released from multivesicular endosomes. PMPs may directly stimulate other cells (e.g., hematopoietic cells, lymphocytes and endothelium), transfer platelet expressed receptors (e.g., CD41 or CXCR4) to the surface of other cells, and, in some situations, transfer mRNA, proteins, and even infectious particles to the target cells. Interestingly, in healthy donors, the majority of circulating CD41+ PMPs do not express surface activation marker CD62P, suggesting that they do not originate from activated platelets. In a very elegant study, Flaumenhaft et al. report that a significant number of circulating CD41+ MPs in healthy individuals are derived directly from Mks. Authors first demonstrated via electron microscopy of spontaneous formation of Mk-derived MPs (MkMPs) from cultured murine Mk and that these MkMPs were different from PMPs. However, a functional role for MkMPs was not revealed until a recent study, which documented a novel biological role of MkMPs that are able to induce HSC differentiation towards the Mk lineage without exogenous TPO stimulation. In this paper, Jiang et al. demonstrated that MkMPs, which are distinct from Mk exosomes, target HSC with high specificity since they have no effect on other BM-resident cells, such as mesenchymal stem cells, endothelial cells or granulocytes. They showed that both endocytosis and membrane fusion were responsible for the delivery of MkMP cargo to HSCs, and that MkMPs attached to and entered HSCs preferentially through their uropods, with CD54, CD11b, CD18 and CD43 being involved in target-cell recognition. Aside from the role of EVs in the Mk-HSC crosstalk in the BM under physiological conditions, we can speculate that EV trafficking may also play a distinct role in deregulated hematopoiesis during fibrotic progression (Figure 1). Interestingly, increased MP generation under high shear stress has been reported in platelets in the presence of TPO, a main trigger of BM fibrosis in human and mice.
Megakaryocyte-derived pro-fibrotic cytokines in bone marrow fibrosis
|Table 1. List of Mk-derived cytokines implicated in bone marrow fibrosis progression.|
Platelet-Derived Growth Factor (PDGF). PDGF is one of the first growth factors that has been implicated in the role of Mk in development of BM fibrosis. PDGF is produced by Mks in the BM and is physiologically carried to the circulation in the α-granules of the platelets to act at the site of tissue injury as a mediator of tissue repair. PDGF receptors (PDGFRs) are members of the membrane tyrosin-kinase family, composed of the two subunits PDGFRα and PDGFRβ, which form homo- or heterodimers. In the context of tissue repair, the PDGF/PDGFR axis not only enhances the replication, survival, and migration of myofibroblasts but also modulates the production and release of several pro- and anti-inflammatory mediators in fibrotic diseases. Interestingly, PDGF has been reported to increase the expression of the collagen cross-linking enzyme, Lysil Oxidase (LOX), which in turn, oxidizes the PDGF receptor on smooth muscle cells, fibroblasts, and Mks, enhancing the proliferation signaling from this cytokine.[83,84] Ultimately, this loop has the potential to further boost the fibrotic phenotype.
Increased levels of PDGF in plasma and urine from patients with MPNs have been reported.[86,87] Further, Mks and erythroid precursors contained increased levels of immunohistochemically detectable PDGF in BM biopsies of PMF patients. The expression of members of the PDGF system in BM cells derived from PMF patients has been also investigated by real-time RT-PCR.
Increased expression of PDGFs could be demonstrated to be a feature of advanced fibrosis in PMF that is not demonstrable in the pre-fibrotic phase of the disease.
Differently from their ligands, up-regulation of both PDGFRs during fibrotic progression is more controversial. In normal BM PDGFRα appeared in endothelial and endosteal cells in addition to strong labeling in Mks and platelets. In contrast, PDGFRβ subunit marked perisinusoidal stromal cells and adventitial fibrocytes of the larger vessels. However, in PMF patients, Bedekovics et al. found that PDGFRβ expression closely correlates with the grade of MF, while this was not evident for PDGFRα. On the contrary, Bock et al. reported a strong up-regulation of the PDGFRα in patients with advanced myelofibrosis.
Recently, the involvement of the PDGF/PDGFR axis in BM fibrosis has been definitively proven. Conditional deletion of the PDGFR-α gene and inhibition of PDGFRα by imatinib in leptin receptor+ stromal cells was shown to suppress their expansion and to ameliorate BM fibrosis in mice.
Transforming Growth Factor-β (TGF-β). Among the abnormally expressed cytokines in PMF, TGF-β1 has received attention due to its critical role in inducing fibrosis not only in BM, but also in other organs. TGF-β occurs in 3 isoforms: TGFβ1, TGFβ2 and TGFβ3. TGFβ1 is the most abundant of all these isoforms and platelets, Mks and monocytes cells are sources of TGF-β production. TGFβ1 is secreted as latent protein and is stored in the extracellular matrix. Reactive oxygen species, proteases, integrins and thrombospondin-1 (TSP-1), convert the inactive latent complexes to the active forms.
Once activated, TGFβ-1 induces BM fibrosis on one hand, by increasing the synthesis of types I, III and IV collagen, FN, proteoglycans and tenascin; while on the other hand, by decreasing matrix degradation through down-regulation of metalloproteinases (MMPs), particularly MMP3, and up- regulation of tissue inhibitors of metalloproteinase (TIMP), particularly TIMP-1. However, effects of TGF-β1 are not restricted to the stromal compartment and TGF-β1-mediated changes to the BM niche remain to be fully elucidated. It is well known that TGF-β has direct effects on hematopoietic cells by negatively regulating granulocyte, erythroid, Mk and macrophage progenitor proliferation. Further, Erba et al. showed that release and activation of TGF-β1 by Mks and platelets, forced endothelial cells from the BM microvasculature of PMF patients, and mouse model of PMF, to acquire a mesenchymal phenotype through Endothelial Mesenchymal Transition (EndMT), during the development of fibrosis.
Not surprisingly, several groups reported on quantitative alterations of TGF-β and its receptors in Mk, platelets, and CD34+ progenitor cells from MPN patients and concluded that TGF-β was involved in myelofibrosis and myeloproliferation.[31,98-100] In addition to quantitative alterations, Ciaffoni et al., recently demonstrated abnormalities in TGF-β1 signaling genes in the marrow and spleen of PMF patients. These alterations included genes of TGF-β1 signaling, cell cycling, Hedgehog and p53 signaling and suggested a non-canonical TGF-β1 signaling in marrow identifying, for the first time, autoimmunity as a possible cause of BM fibrosis in PMF. Among the genes that predict the activation of the non-canonical TGF-β signaling, expression level of the Jun gene was increased in BM of PMF patients. Interestingly, over-expression of Jun was sufficient to induce myelofibrosis, severe fibrosis in multiple organs and steatohepatosis in mice.
Moreover, the involvement of TGF-β in in vivo mouse model has been deeply investigated. TGF-β was significantly increased in the extracellular fluid of the BM, plasma and platelet extracts in two widely MF studied mouse models, which include the TPOhigh and the GATA-1low mice.[103,104] To test directly the impact of TGF-β1 in the pathogenesis of MF, BM stem cells from homozygous TGF-β1 null (TGF-β1(-/-)) and wild-type littermates were infected with a retrovirus encoding the murine TPO protein and engrafted into lethally irradiated wild type hosts for long-term reconstitution. Differently from wild type mice, none of the mice repopulated with TGF-β1(-/-) cells showed deposition of reticulin fibres at any time during the follow-up. Consistently with patient data, alterations of TGF-β1, Hedgehog, and p53 signaling pathways were identified in the BM of GATA- 1low mice model. Inhibition of TGF-β1 signaling in these mice by an inhibitor of the tyrosine kinase activity of TGF-β1 receptor type I, led to restoration of normal Mk development, reduced fibrosis, neoangiogenesis, and osteogenesis in the BM. Based on these consistent observations, TGF-β inhibition has become a potential therapeutic strategy to decrease BM fibrosis in MPNs and is also being investigated in several clinical and experimental scenarios.
Cxcl-4 (Pf-4). Cxcl-4, (C-X-C motif) ligand 4 (CXCL4) (also known as platelet factor 4 [PF4]), is one of the most abundant protein in the α-granules of Mk/platelets (estimated micromolar concentration), together with CXCL7. This 70 a.a., cationic, lysine-rich, 7.8-kDa chemokine, is mainly synthesized by Mks, and comprises 2%-3% of the releasate from agonist-activated platelets. Once secreted, CXCL4 avidly binds to glycosaminoglycans, but only a splice-variant of the human chemokine receptor CXCR3 (CXCR3B), which is not present in mice, and LDLR90 have been identified as high-affinity receptors. In contrast, the specific receptor for CXCL4 has not yet been identified in mice. However, in some circumstances, CXCL4 can interact with other chemokines (e.g. CCL5) and thereby modulate their effects on target cells. A central role of platelet-derived CXCL4 was demonstrated in solid organs. In vivo, mice lacking CXCL4 are significantly protected from severe liver fibrosis, demonstrating the pro-fibrotic phenotype of this chemokine and that its effects in mice are indeed mediated by other receptors than CXCR3. In addition, it was shown that CXCL4 is secreted not only by activated platelets, but also by plasmacytoid dendritic cells and fibroblasts in systemic sclerosis. Thus, these studies further involve Mks/platelets to pro- inflammatory and pro-fibrotic programmes in fibrosis. Interestingly, more than 30 years ago, Burstein et al. linked CXCL4 to myelofibrosis, by suggesting that abnormal Mks stimulate the proliferation of fibrosis-driving fibroblasts though the release of CXCL4. However, no correlation was seen between BM fibrosis and plasma levels or the platelet content of CXCL4 in the same study. Recently, Schneider et al. using a mouse model with genetic fate tracing in vivo, provided evidence that Gli1+ cells are key players in the initiation and progression of BM fibrosis and that Mk-derived CXCL4 was necessary and sufficient to induce the migration of Gli1+ stromal cells and their myofibroblastic differentiation. In these experiments, CXCL4 was shown to induced myofibroblast differentiation of Gli1+ cells comparable to induction with TGF-β, a known stimulus for differentiation of MSCs into myofibroblasts.
Other cytokines. Oncostatin M (OSM), is a pleiotropic cytokine belonging to the interleukin-6 (IL-6) family. Produced mainly by activated T cells and monocytes, OSM can elicit different biological effects, depending on the cell type. OSM acts through two types of receptors. The type I OSM receptor is composed of gp130 and the leukemia inhibitory factor (LIF) receptor β-subunit (LIFR), and the type II OSM receptor is composed of gp130 and the OSM-specific receptor β- subunit (OSMR). OSM has emerged as an important cytokine in the control of hematopoiesis. Transplantation experiments with OSM-deficient mice have shown that OSM stimulates stromal cells as well as hematopoietic progenitors and is required for the proper generation and maintenance of microenvironment in the BM.[116,117] Noteworthy, BM Mks express substantial amounts of OSM, and OSM has been reported to behave as a megakaryocytic maturation factor in vitro and to augment platelet production in vivo. Within the context of myelofibrosis, JAK2 V617F mutation promotes expression of OSM in neoplastic myeloid cells and, consequently, OSM mRNA levels are increased in the BM of patients with MPNs compared to control patients. Mechanistically, OSM secreted by JAK2V617F+ cells stimulated growth of fibroblasts and endothelial cells by sustaining the production of angiogenic and pro-fibrogenic cytokines.
Aberrant packaging of α-granule-specific proteins is supposed to trigger myelofibrosis in patients with GPS. Using a Nbeal2-/- murine model of GPS, Guerrero et al. demonstrated that BM Mks from these mice were enriched in a restricted set of chemokines transcripts, namely CCL3 and CCL4, which encode macrophage inflammatory protein (MIP) 1α and 1β, respectively, well-known pro- inflammatory chemokines increased in PMF. A peculiar role for MIP 1α in sustaining osteoblasts proliferation in MPN mice model has been also proposed.
Interleukin 8 (IL-8) is a member of the family of chemokines related by a CXC motif. It binds to CXC chemokine receptor 1 (CXCR1) and 2 (CXCR2). It is produced by several cell types, including Mks and exhibits many biological functions in inflammation, HSC proliferation and mobilization and neo-angiogenesis. Increased levels of IL-8 were found in serum and plasma of patients with PMF. Additionally, IL-8 and its receptors were reported to be involved in PMF-altered Mk growth. Finally, rodents lack a direct homologue of IL-8, but the chemokines CXCL1/KC, CXCL2/MIP-2, and CXCL5-6/LIX are regarded as functional homologues of IL-8.
Finally, Mks were repeatedly identified as the main cellular source of an increasing list of cytokines, which show higher plasma levels in PMF patients, and that are individually involved in the promotion of myelofibrosis. This list further includes bone morphogenic proteins (e.g. BMP- 1, BMP-2, -4, and -6), Lipocalin-2 (LCN-2), Fibroblasts Growth Factor (FGF), Vascular Endothelial Growth Factor (VEGF), Secreted Phospho Protein-1 (SPP1) and Thrombospondin- 1 (TSP-1).[132,133]
Megakaryocyte expression of extracellular matrices and cross-linking enzymes in bone marrow fibrosis
In parallel with ECM secretion, Mks express several modifiers of ECM structure. Factor XIII-A is synthesized by Mks and both protein and mRNA are packaged into the cytoplasm of forming platelets. Factor XIII-A belongs to transglutaminases, a class of calcium ion-dependent enzymes that catalyze an acyl transfer reaction in which y-carboxamide groups of peptide-bound glutaminyl residues are acyl donors and primary amine including the δ-amino group of peptide-bound lysyl residues, are acyl acceptors. By this reaction, transglutaminases catalyze the formation of δ-(y- glutamy1) lysine linkages between proteins. Thus, based on these properties, the potential role of FXIII-A in the BM environment may consist in the cross-link of extracellular fibrillar FN matrix with collagen.[138,139]
LOX is a copper-dependent amine oxidase that catalyzes oxidative deamination of lysine and hydroxylysine residues on collagen and elastin, leading to cross-linking within these proteins and changes in ECM elasticity. Eliades et al., detected LOX expression in diploid-tetraploid Mks, but scarce traces in polyploid Mks and identified a peculiar role for this enzyme in BM fibrosis. They found that in the GATA-1low mouse model, which is characterized by increased frequency of low ploidy Mks and extensive matrix of fibres, LOX was abundantly expressed by low ploidy Mks. More importantly, administration of β-aminopropionitrile (a LOX inhibitor) to the GATA-1low mice inhibited the progression of myelofibrosis. Consistently, human platelets and Mks from patients with PMF overexpress LOX and show higher adhesion to collagen that is dependent on LOX activity.
In addition to cross-linking enzymes, also ECM degradation directly impacts cell behavior and migration. Metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases and function in remodeling the ECM by its ability to degrade and cleave ECM components with wide substrate specificities. Once activated, the MMPs are subject to inhibition by the tissue inhibitors of metalloproteinases (TIMPs) that bind MMPs non-covalently and counteract their proteolytic activity.
Mks synthetize several MMPs, particularly gelatinases MMP-2 and MMP-9. Moreover, transcripts for MMP-1, 11, 14, 15, 17, 19, 24 and 25 have also been identified. Conversely, biosynthesis of TIMPs 1-4 in Mks/platelets intervenes in excessive tissue remodeling. It is suggested that BM fibrosis in PMF results from enhanced TIMP and decreased MMP activities. In particular, TIMP-1 (both the total, complex and the free form) is significantly increased in MPNs, while MMP-3 is significantly decreased, and levels of MMP-2 and MMP-9 are not different from control values.[95,144] Further, membrane type 1-MMP (MMP-14) was found overexpressed by up to 80-fold in advanced stages of fibrosis, and Mks and endothelial cells were unmasked as the major cellular source. By contrast, a significantly higher expression of neutrophil collagenase (MMP-8) was encountered in the pre-fibrotic stages of PMF. Although the JAK-STAT signaling pathway is directly involved in the regulation of genes encoding MMPs, the altered expression of MMPs seem not influenced by the JAK2 mutation status but predominantly related to the stage of disease.
Direct Megakaryocyte-cell interactions in the context of bone marrow fibrosis
Abnormalities in mesenchymal stem cells derived from PMF patients were reported to alter the ability of these cells to support Mk differentiation in vitro.[147-149] Further, a pathological interaction, between polymorphonuclear (PMN) leukocytes and Mk, correlated with MF development, has been also proposed. Emperipolesis is the random passage of the different types of BM cells through Mk intracellular space. The phenomenon is strongly increased in BM of patients with MPN disorders. Schmitt et al., first showed both in the BM of patients with PMF, and in the TPOhigh murine model, abnormal subcellular P-selectin distribution, which appeared to correlate with excessive and pathological emperipolesis of PMN leukocytes within Mk. This abnormal interaction was considered the main cause of the destruction of Mk storage organelles and leakage of α-granular contents into the BM microenvironment. As in patients, a similar pathologic neutrophil emperipolesis was detected in the GATA-1low mouse model of myelofibrosis. In BM Mk of these mice, P-selectin, although normally expressed, was found frequently associated with the demarcation membrane system (DMS) instead of within granules. In addition, pathologic Mks were surrounded by myeloperoxidase-positive neutrophils, some of which appeared in the process to establish contact with Mks by fusing their membrane with those of the DMS. Quantification of this process revealed that 34% (in BM) of GATA-1(low) Mks contained 1 to 3 neutrophils embedded in a vacuolated cytoplasm. The neutrophil-embedded GATA-1(low) Mks displayed morphologic features compatible with those of cells dying from para-apoptosis, confirming the hypothesis that emperipolesis sustains myelofibrosis by driving the release of fibrogenic Mk cytokines and neutrophil proteases in the BM microenvironment. Moreover, abnormal localization of P-selectin in Mks and platelets, induced by the GATA-1(low) mutation, was further involved in the pathological interactions of circulating platelets with leucocytes, responsible for the increased presence of thrombosis seen in these mice, as well as, in the promotion of extramedullary hematopoiesis. Consistently, high rate of emperipolesis is detectable in BM biopsies of patients with GPS, a rare inherited bleeding disorder characterized by deficiency of platelet α-granules, macrothrombocytopenia and marrow fibrosis.
Is the pro-fibrotic role of Megakaryocytes/ platelets restricted to the bone marrow?
|Table 2. Megakaryocytes/Platelets contribution to organ fibrosis.|
A large amount of experimental evidence implies that platelets participate in the liver fibrotic process mainly by releasing pro- fibrotic mediators. Using mice carrying a Mk/platelet-specific targeted conditional deletion of the TGF-β1 gene (PF4CreTgfβ1f/f), Ghafoory et al. demonstrated that platelet TGF-β1 deficiency decreases liver fibrosis in a mouse model of carbon tetrachloride (CCl4)-induced liver injury. However, there is also evidence that platelets under certain circumstances may have a protective role against liver fibrosis. To this regard, thrombocytopenic mice, with selective disruption of the anti-apoptotic gene Bcl-xL, were shown to be more prone to liver fibrosis by bile duct ligation compared to their wild type counterparts. The authors, suggested that the anti-fibrotic Hepatocyte Growth Factor (HGF) released from activated platelets in liver, attenuated the expression of collagen in hepatic stellate cells, the key cell type in liver fibrosis. Additionally, Mk-specific disruption of the TGF-β1 gene resulted in mice protection from cardiac hypertrophy, fibrosis, and systolic dysfunction in response to transverse aortic constriction, suggesting that platelet profibrotic behavior is not solely restricted to the liver. Similarly, evidence has been accumulated implicating platelets in the pathogenesis of interstitial lung fibrosis in several animal models. Piguet et al. found that trapping of platelets in contact with the alveolar endothelium of the lungs after bleomycin injection was increased and correlated with the deposition of collagen. The authors suggested that this could represent not only a simple correlation but also a potential pathological mechanism that links platelets and pulmonary fibrosis. Interestingly, in a recent study platelets were shown to promote acute lung injury through the massive release of the Wnt/β-catenin inhibitor Dickkopf-1 (Dkk-1) from their α-granules, leading to increased expression of vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1) on the surface of alveolar epithelial cells (AECs) and abnormal macrophage/neutrophils interaction with AECs. In addition to the direct involvement of platelets in fibrosis of solid organs, the potential contribution of Mks to organ fibrosis still needs to be uncovered. It is becoming increasingly clear that Mks transfer unique genetic codes to platelets, and that environmental changes can alter transcriptional, translational, and post-translational processes in Mks, affecting the genetic code of platelets in circulation. Change in Mk-platelet transcriptional axis is a dynamic process, especially in disease situations, and can rapidly affect the platelet repertoire of messenger RNAs (mRNAs), microRNAs (miRNAs), and proteins that contribute to their primary and alternative functions. Freishtat et al., revealed for the first time, that a de novo transcriptome is imparted to platelets by BM residing Mks during sepsis. Septic Mks produce platelets with acutely altered mRNA profiles, and these platelets mediate lymphotoxicity via the potent cytotoxic serine protease, granzyme B. Similarly, in the context of cancer, Mks of tumor-bearing mice endocytose circulating thrombospondin-1 (TSP-1) and increase its synthesis to produce platelets with elevated levels of TSP-1, one of the most potent angiogenesis inhibitors. These TSP-1-enriched platelets were shown to adhere to tumors and to act as potent inhibitors of angiogenesis and cancer growth. Thus, similar changes may occur in fibrotic conditions, but this has not been demonstrated yet.
|Figure 2. Schematic representation of potential novel mechanisms for MPN pathogenesis.|
- Kuter DJ, Bain B, Mufti G, Bagg A, Hasserjian RP.
Bone marrow fibrosis: pathophysiology and clinical significance of
increased bone marrow stromal fibres. Br J Haematol.
- Gianelli U, Fiori S, Cattaneo D, et al.
Prognostic significance of a comprehensive histological evaluation of
reticulin fibrosis, collagen deposition and osteosclerosis in primary
myelofibrosis patients. Histopathology. 2017;71(6):897-908.
C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading
to constitutive signalling causes polycythaemia vera. Nature.
- Pikman Y, Lee BH, Mercher T, et al.
MPLW515L is a novel somatic activating mutation in myelofibrosis with
myeloid metaplasia. PLoS Med. 2006;3(7):e270.
- Pardanani AD, Levine RL, Lasho T, et
al. MPL515 mutations in myeloproliferative and other myeloid disorders:
a study of 1182 patients. Blood. 2006;108(10):3472-3476.
T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of
calreticulin in myeloproliferative neoplasms. N Engl J Med.
- Nangalia J, Massie CE, Baxter EJ, et al.
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated
JAK2. N Engl J Med. 2013;369(25):2391-2405.
https://doi.org/10.1056/NEJMoa1312542 PMid:24325359 PMCid:PMC3966280
- Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin. 2009;59(3):171-191. https://doi.org/10.3322/caac.20009 PMid:19369682
RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post
polycythemia vera myelofibrosis (post-PV MF), post essential
thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP):
Consensus on terminology by the international working group for
myelofibrosis research and treatment (IWG-MRT). Leuk Res.
- Cervantes F, Dupriez B, Pereira A, et al.
New prognostic scoring system for primary myelofibrosis based on a
study of the International Working Group for Myelofibrosis Research and
Treatment. Blood. 2009;113(13):2895-2901.
SO, Merchant D, Mahmud N, et al. Pivotal contributions of
megakaryocytes to the biology of idiopathic myelofibrosis. Blood.
- Avecilla ST, Hattori K,
Heissig B, et al. Chemokine-mediated interaction of hematopoietic
progenitors with the bone marrow vascular niche is required for
thrombopoiesis. Nat Med. 2004;10(1):64-71.
I, Lucas D, Pinho S, et al. Megakaryocytes regulate hematopoietic stem
cell quiescence through CXCL4 secretion. Nat Med.
2014;20(11):1315-1320. https://doi.org/10.1038/nm.3707 PMid:25326802
- Zhao M, Perry JM, Marshall H, et al.
Megakaryocytes maintain homeostatic quiescence and promote post-injury
regeneration of hematopoietic stem cells. Nat Med.
- Winter O, Moser K, Mohr E, et al.
Megakaryocytes constitute a functional component of a plasma cell niche
in the bone marrow. Blood. 2010;116(11):1867-1875.
TS, Caselli A, Otsuru S, et al. Megakaryocytes promote murine
osteoblastic HSC niche expansion and stem cell engraftment after
radioablative conditioning. Blood. 2013;121(26):5238-5249.
- Schmitt A, Jouault H, Guichard J,
Wendling F, Drouin A, Cramer EM. Pathologic interaction between
megakaryocytes and polymorphonuclear leukocytes in myelofibrosis.
Blood. 2000;96(4):1342-1347. PMid:10942376
K. The molecular mechanisms that control thrombopoiesis. J Clin Invest.
2005;115(12):3339-3347. https://doi.org/10.1172/JCI26674 PMid:16322778
- Shivdasani RA, Rosenblatt MF,
Zucker-Franklin D, et al. Transcription factor NF-E2 is required for
platelet formation independent of the actions of thrombopoietin/MGDF in
megakaryocyte development. Cell. 1995;81(5):695-704.
SR, Hartwig JH, Italiano JE. The biogenesis of platelets from
megakaryocyte proplatelets. J Clin Invest. 2005;115(12):3348-3354.
https://doi.org/10.1172/JCI26891 PMid:16322779 PMCid:PMC1297261
P, Flaumenhaft R. Platelet alpha-granules: basic biology and clinical
correlates. Blood Rev. 2009;23(4):177-189.
- Maynard DM, Heijnen HF, Gahl WA,
Gunay-Aygun M. The α-granule proteome: novel proteins in normal and
ghost granules in gray platelet syndrome. J Thromb Haemost.
- Stellos K, Langer H,
Daub K, et al. Platelet-derived stromal cell-derived factor-1 regulates
adhesion and promotes differentiation of human CD34+ cells to
endothelial progenitor cells. Circulation. 2008;117(2):206-215.
EM, Markens BA, Italiano JE. Release of angiogenesis regulatory
proteins from platelet alpha granules: modulation of physiologic and
pathologic angiogenesis. Blood. 2011;118(5):1359-1369.
- Coppinger JA, Cagney G, Toomey S, et
al. Characterization of the proteins released from activated platelets
leads to localization of novel platelet proteins in human
atherosclerotic lesions. Blood. 2004;103(6):2096-2104.
L, Tolley ND, Michetti N, Bury L, Weyrich AS, Gresele P. Megakaryocytes
differentially sort mRNAs for matrix metalloproteinases and their
inhibitors into platelets: a mechanism for regulating synthetic events.
- Handagama P, Scarborough RM, Shuman
MA, Bainton DF. Endocytosis of fibrinogen into megakaryocyte and
platelet alpha-granules is mediated by alpha IIb beta 3 (glycoprotein
IIb-IIIa). Blood. 1993;82(1):135-138. PMid:8391871
JN. Platelet immunoglobulin G: its significance for the evaluation of
thrombocytopenia and for understanding the origin of alpha-granule
proteins. Blood. 1990;76(5):859-870. PMid:2203482
S, Emiliani C, Guglielmini G, Orlacchio A, Nenci GG, Gresele P.
Platelets release their lysosomal content in vivo in humans upon
activation. Thromb Haemost. 2000;83(1):157-164.
A, Israels SJ. Platelet dense granules: structure, function and
implications for haemostasis. Thromb Res. 1999;95(1):1-18.
S, Di Buduo CA, Campanelli R, et al. Involvement of TGFβ1 in autocrine
regulation of proplatelet formation in healthy subjects and patients
with primary myelofibrosis. Haematologica. 2013;98(4):514-517.
- Balduini A, Di Buduo CA, Malara A, et
al. Constitutively released adenosine diphosphate regulates proplatelet
formation by human megakaryocytes. Haematologica. 2012;97(11):1657-
1665. https://doi.org/10.3324/haematol.2011.059212 PMid:22689668
- Saulle E, Guerriero R, Petronelli A,
et al. Autocrine role of angiopoietins during megakaryocytic
differentiation. PLoS One. 2012;7(7):e39796.
- Lambert MP, Rauova L, Bailey M,
Sola-Visner MC, Kowalska MA, Poncz M. Platelet factor 4 is a negative
autocrine in vivo regulator of megakaryopoiesis: clinical and
therapeutic implications. Blood. 2007;110(4):1153-1160.
- Nagata Y, Yoshikawa J, Hashimoto A,
Yamamoto M, Payne AH, Todokoro K. Proplatelet formation of
megakaryocytes is triggered by autocrine-synthesized estradiol. Genes
Dev. 2003;17(23):2864-2869. https://doi.org/10.1101/gad.1128003
- Casella I, Feccia T,
Chelucci C, et al. Autocrine-paracrine VEGF loops potentiate the
maturation of megakaryocytic precursors through Flt1 receptor. Blood.
- Malara A, Abbonante V, Di Buduo CA, Tozzi
L, Currao M, Balduini A. The secret life of a megakaryocyte: emerging
roles in bone marrow homeostasis control. Cell Mol Life Sci.
- Clemetson KJ. Platelets
and primary haemostasis. Thromb Res. 2012;129(3):220-224.
A, Rinckel JY, Proamer F, et al. Respective contributions of single and
compound granule fusion to secretion by activated platelets. Blood.
- Rendu F, Brohard-Bohn B. The platelet
release reaction: granules' constituents, secretion and functions.
EM, Poole AW. Platelet secretion: From haemostasis to wound healing and
beyond. Blood Rev. 2015;29(3):153-162.
- Italiano JE, Richardson JL, Patel-Hett
S, et al. Angiogenesis is regulated by a novel mechanism: pro- and
antiangiogenic proteins are organized into separate platelet alpha
granules and differentially released. Blood. 2008;111(3):1227-1233.
- Ma L, Perini R, McKnight W, et al.
Proteinase-activated receptors 1 and 4 counter-regulate endostatin and
VEGF release from human platelets. Proc Natl Acad Sci U S A.
2005;102(1):216- 220. https://doi.org/10.1073/pnas.0406682102
- Kamykowski J, Carlton P,
Sehgal S, Storrie B. Quantitative immunofluorescence mapping reveals
little functional coclustering of proteins within platelet α-granules.
M, Fabucci ME, Bosco D, et al. Differential localization of P-selectin
and von Willebrand factor during megakaryocyte maturation. Biotech
- Guerrero JA, Bennett C, van der Weyden
L, et al. Gray platelet syndrome: proinflammatory megakaryocytes and
α-granule loss cause myelofibrosis and confer metastasis resistance in
mice. Blood. 2014;124(24):3624-3635.
J, Kuemmel T, Sander C, Fischer R. Ultrastructure of bone marrow tissue
in so-called primary (idiopathic) myelofibrosis-osteomyelosclerosis
(agnogenic myeloid metaplasia). I. Abnormalities of megakaryopoiesis
and thrombocytes. J Submicrosc Cytol Pathol. 1991;23(1):93- 107.
- Raman BK, Van Slyck EJ, Riddle J, Sawdyk
MA, Abraham JP, Saeed SM. Platelet function and structure in
myeloproliferative disease, myelodysplastic syndrome, and secondary
thrombocytosis. Am J Clin Pathol. 1989;91(6):647-655.
S, Curci G, Piccinini L, et al. Platelet alpha-granule release in
chronic myeloproliferative disorders with thrombocytosis. Scand J Clin
Lab Invest. 1986;46(2):163-166.
- Holme S, Murphy S. Platelet abnormalities in myeloproliferative disorders. Clin Lab Med. 1990;10(4):873-888. PMid:2272179
V, Clancy JW, Sedgwick A, D'Souza-Schorey C. Microvesicles: mediators
of extracellular communication during cancer progression. J Cell Sci.
2010;123(Pt 10):1603-1611. https://doi.org/10.1242/jcs.064386
- Raposo G, Stoorvogel W.
Extracellular vesicles: exosomes, microvesicles, and friends. J Cell
Biol. 2013;200(4):373-383. https://doi.org/10.1083/jcb.201211138
- Costa Verdera H,
Gitz-Francois JJ, Schiffelers RM, Vader P. Cellular uptake of
extracellular vesicles is mediated by clathrin-independent endocytosis
and macropinocytosis. J Control Release. 2017;266:100-108.
M, Gutiérrez-Vázquez C, Villarroya-Beltri C, et al. Unidirectional
transfer of microRNA-loaded exosomes from T cells to antigen-presenting
cells. Nat Commun. 2011;2:282. https://doi.org/10.1038/ncomms1285
- Goloviznina NA, Verghese
SC, Yoon YM, Taratula O, Marks DL, Kurre P. Mesenchymal Stromal
Cell-derived Extracellular Vesicles Promote Myeloid-biased Multipotent
Hematopoietic Progenitor Expansion via Toll-Like Receptor Engagement. J
Biol Chem. 2016;291(47):24607- 24617.
https://doi.org/10.1074/jbc.M116.745653 PMid:27758863 PMCid:PMC5114412
E, Van Damme M, Pieters K, et al. Extracellular vesicles of bone marrow
stromal cells rescue chronic lymphocytic leukemia B cells from
apoptosis, enhance their migration and induce gene expression
modifications. Haematologica. 2017;102(9):1594-1604.
- Lin LY, Du LM, Cao K, et al. Tumour
cell-derived exosomes endow mesenchymal stromal cells with
tumour-promotion capabilities. Oncogene. 2016;35(46):6038-6042.
https://doi.org/10.1038/onc.2016.131 PMid:27132512 PMCid:PMC5116561
P. The nature and significance of platelet products in human plasma. Br
J Haematol. 1967;13(3):269-288.
E, Duchez AC, Brisson A. The diversity of platelet microparticles. Curr
Opin Hematol. 2015;22(5):437-444.
M, Majka M, Pratico D, et al. Platelet-derived microparticles stimulate
proliferation, survival, adhesion, and chemotaxis of hematopoietic
cells. Exp Hematol. 2002;30(5):450-459.
T, Majka M, Kijowski J, et al. Platelet- and megakaryocyte-derived
microparticles transfer CXCR4 receptor to CXCR4-null cells and make
them susceptible to infection by X4-HIV. AIDS. 2003;17(1):33-42.
MZ. Megakaryocyte-derived microvesicles, please stand up! Blood.
- Flaumenhaft R, Dilks JR, Richardson J, et
al. Megakaryocyte-derived microparticles: direct visualization and
distinction from platelet-derived microparticles. Blood.
- Jiang J, Kao CY,
Papoutsakis ET. How do megakaryocytic microparticles target and deliver
cargo to alter the fate of hematopoietic stem cells? J Control Release.
- Nomura S, Nakamura T, Cone
J, Tandon NN, Kambayashi J. Cytometric analysis of high shear-induced
platelet microparticles and effect of cytokines on microparticle
generation. Cytometry. 2000;40(3):173-181.
- Vainchenker W, Kralovics R. Genetic basis and
molecular pathophysiology of classical myeloproliferative neoplasms.
C, Martinaud C, Ruzehaji N, Le Bousse-Kerdilès MC. Inflammation as a
Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis.
Mediators Inflamm. 2015;2015:415024.
https://doi.org/10.1155/2015/415024 PMid:26640324 PMCid:PMC4660030
A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating
interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently
prognostic in primary myelofibrosis: a comprehensive cytokine profiling
study. J Clin Oncol. 2011;29(10):1356-1363.
HC. Perspectives on chronic inflammation in essential thrombocythemia,
polycythemia vera, and myelofibrosis: is chronic inflammation a trigger
and driver of clonal evolution and development of accelerated
atherosclerosis and second cancer? Blood. 2012;119(14):3219-3225.
HK, Griesshammer M, le Coutre P, et al. Safety and efficacy of
ruxolitinib in an open-label, multicenter, single-arm phase 3b
expanded-access study in patients with myelofibrosis: a snapshot of
1144 patients in the JUMP trial. Haematologica. 2016;101(9):1065-1073.
- Skoda RC, Duek A, Grisouard J.
Pathogenesis of myeloproliferative neoplasms. Exp Hematol.
- Zhan H, Ma Y, Lin CH, Kaushansky K. JAK2.
Leukemia. 2016;30(12):2332-2341. https://doi.org/10.1038/leu.2016.114
- Kuter DJ, Mufti GJ, Bain
BJ, Hasserjian RP, Davis W, Rutstein M. Evaluation of bone marrow
reticulin formation in chronic immune thrombocytopenia patients treated
with romiplostim. Blood. 2009;114(18):3748-3756.
JL, Cohen-Solal K, Tulliez M, et al. High thrombopoietin production by
hematopoietic cells induces a fatal myeloproliferative syndrome in
mice. Blood. 1997;90(11):4369- 4383. PMid:9373248
AM, Bianchi L, Cellai C, et al. Development of myelofibrosis in mice
genetically impaired for GATA-1 expression (GATA-1(low) mice). Blood.
- Jantunen E, Hänninen A, Naukkarinen A,
Vornanen M, Lahtinen R. Gray platelet syndrome with splenomegaly and
signs of extramedullary hematopoiesis: a case report with review of the
literature. Am J Hematol. 1994;46(3):218-224.
P, Narayanan R, Qian J, Denny TN, Colon C, Gascon P. NF-kappa B as a
central mediator in the induction of TGF-beta in monocytes from
patients with idiopathic myelofibrosis: an inflammatory response beyond
the realm of homeostasis. J Immunol. 2000;165(4):2271-2277.
BM, Rafii S, Teterson M, Eaton D, Crystal RG, Moore MA.
Adenovector-mediated expression of human thrombopoietin cDNA in
immune-compromised mice: insights into the pathophysiology of
osteomyelofibrosis. J Immunol. 1998;160(2):691-699. PMid:9551904
O, Chagraoui H, Prina E, et al. Monocyte/macrophage dysfunctions do not
impair the promotion of myelofibrosis by high levels of thrombopoietin.
J Immunol. 2006;176(11):6425-6433.
H, Jhanwar SC. Properties of myelofibrosis-derived fibroblasts. Prog
Clin Biol Res. 1984;154:307-322. PMid:6382300
DF, Raines EW. History of discovery: platelet-derived growth factor.
Arterioscler Thromb Vasc Biol. 2011;31(11):2397-2401.
- Bonner JC. Regulation of PDGF and its
receptors in fibrotic diseases. Cytokine Growth Factor Rev.
- Lucero HA, Ravid K, Grimsby JL, et al.
Lysyl oxidase oxidizes cell membrane proteins and enhances the
chemotactic response of vascular smooth muscle cells. J Biol Chem.
- Eliades A,
Papadantonakis N, Bhupatiraju A, et al. Control of megakaryocyte
expansion and bone marrow fibrosis by lysyl oxidase. J Biol Chem.
- Papadantonakis N,
Matsuura S, Ravid K. Megakaryocyte pathology and bone marrow fibrosis:
the lysyl oxidase connection. Blood. 2012;120(9):1774-1781.
- Gersuk GM, Carmel R, Pattengale PK.
Platelet-derived growth factor concentrations in platelet-poor plasma
and urine from patients with myeloproliferative disorders. Blood.
- Lev PR, Marta RF,
Vassallu P, Molinas FC. Variation of PDGF, TGFbeta, and bFGF levels in
essential thrombocythemia patients treated with anagrelide. Am J
Hematol. 2002;70(2):85-91. https://doi.org/10.1002/ajh.10091
- Yoon SY, Tefferi A, Li CY. Cellular
distribution of platelet-derived growth factor, transforming growth
factor-beta, basic fibroblast growth factor, and their receptors in
normal bone marrow. Acta Haematol. 2000;104(4):151-157.
- Bock O,
Loch G, Büsche G, von Wasielewski R, Schlué J, Kreipe H. Aberrant
expression of platelet-derived growth factor (PDGF) and PDGF
receptor-alpha is associated with advanced bone marrow fibrosis in
idiopathic myelofibrosis. Haematologica. 2005;90(1):133-134.
- Bedekovics J, Kiss A, Beke L, Károlyi K,
Méhes G. Platelet derived growth factor receptor- beta (PDGFRβ)
expression is limited to activated stromal cells in the bone marrow and
shows a strong correlation with the grade of myelofibrosis. Virchows
Arch. 2013;463(1):57-65. https://doi.org/10.1007/s00428-013-1434-0
- Decker M, Martinez-Morentin L, Wang G, et
al. Leptin-receptor-expressing bone marrow stromal cells are
myofibroblasts in primary myelofibrosis. Nat Cell Biol.
2017;19(6):677-688. https://doi.org/10.1038/ncb3530 PMid:28481328
- Leask A, Abraham DJ. TGF-beta
signaling and the fibrotic response. FASEB J. 2004;18(7):816-827.
MC, Magdelenat H, Bryckaert MC, Laine-Bidron C, Calvo F. Increased
intraplatelet levels of platelet-derived growth factor and transforming
growth factor-beta in patients with myelofibrosis with myeloid
metaplasia. Br J Haematol. 1991;77(1):80-86.
Bousse-Kerdilès MC, Martyré MC. Dual implication of fibrogenic
cytokines in the pathogenesis of fibrosis and myeloproliferation in
myeloid metaplasia with myelofibrosis. Ann Hematol.
- Wang JC, Novetsky A, Chen C, Novetsky AD.
Plasma matrix metalloproteinase and tissue inhibitor of
metalloproteinase in patients with agnogenic myeloid metaplasia or
idiopathic primary myelofibrosis. Br J Haematol. 2002;119(3):709-712.
U, Karlsson S. The role of Smad signaling in hematopoiesis and
translational hematology. Leukemia. 2011;25(9):1379-1388.
BG, Gruppi C, Corada M, et al. Endothelial-to-Mesenchymal Transition in
Bone Marrow and Spleen of Primary Myelofibrosis. Am J Pathol.
- Le Bousse-Kerdilès MC, Chevillard S,
Charpentier A, et al. Differential expression of transforming growth
factor-beta, basic fibroblast growth factor, and their receptors in
CD34+ hematopoietic progenitor cells from patients with myelofibrosis
and myeloid metaplasia. Blood. 1996;88(12):4534-4546. PMid:8977245
Bousse-Kerdilès MC, Martyré MC, Myelofibrosis FIrnoI. Involvement of
the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of
idiopathic myelofibrosis. Pathol Biol (Paris). 2001;49(2):153-157.
R, Rosti V, Villani L, et al. Evaluation of the bioactive and total
transforming growth factor β1 levels in primary myelofibrosis.
F, Cassella E, Varricchio L, Massa M, Barosi G, Migliaccio AR.
Activation of non- canonical TGF-β1 signaling indicates an autoimmune
mechanism for bone marrow fibrosis in primary myelofibrosis. Blood
Cells Mol Dis. 2015;54(3):234-241.
- Wernig G, Chen SY, Cui L, et al.
Unifying mechanism for different fibrotic diseases. Proc Natl Acad Sci
U S A. 2017;114(18):4757-4762. https://doi.org/10.1073/pnas.1621375114
- Vannucchi AM, Bianchi L,
Paoletti F, et al. A pathobiologic pathway linking thrombopoietin,
GATA-1, and TGF-beta1 in the development of myelofibrosis. Blood.
- Yanagida M, Ide Y, Imai A, et al. The
role of transforming growth factor-beta in PEG- rHuMGDF-induced
reversible myelofibrosis in rats. Br J Haematol. 1997;99(4):739-745.
H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F.
Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in
mice. Blood. 2002;100(10):3495- 3503.
M, Martelli F, Ciaffoni F, et al. Characterization of the TGF-β1
signaling abnormalities in the Gata1low mouse model of myelofibrosis.
- Ceglia I, Dueck AC, Masiello F, et al.
Preclinical rationale for TGF-β inhibition as a therapeutic target for
the treatment of myelofibrosis. Exp Hematol.
- Gleissner CA, von Hundelshausen P, Ley
K. Platelet chemokines in vascular disease. Arterioscler Thromb Vasc
Biol. 2008;28(11):1920-1927. https://doi.org/10.1161/ATVBAHA.108.169417
- Lasagni L, Francalanci
M, Annunziato F, et al. An alternatively spliced variant of CXCR3
mediates the inhibition of endothelial cell growth induced by IP-10,
Mig, and I-TAC, and acts as functional receptor for platelet factor 4.
J Exp Med. 2003;197(11):1537-1549. https://doi.org/10.1084/jem.20021897
- Zaldivar MM, Pauels K,
von Hundelshausen P, et al. CXC chemokine ligand 4 (Cxcl4) is a
platelet-derived mediator of experimental liver fibrosis. Hepatology.
2010;51(4):1345-1353. https://doi.org/10.1002/hep.23435 PMid:20162727
Bon L, Affandi AJ, Broen J, et al. Proteome-wide analysis and CXCL4 as
a biomarker in systemic sclerosis. N Engl J Med. 2014;370(5):433-443.
https://doi.org/10.1056/NEJMoa1114576 PMid:24350901 PMCid:PMC4040466
SA, Malpass TW, Yee E, et al. Platelet factor-4 excretion in
myeloproliferative disease: implications for the aetiology of
myelofibrosis. Br J Haematol. 1984;57(3):383-392.
RK, Mullally A, Dugourd A, et al. Gli1. Cell Stem Cell. 2017;20(6):785-
800.e788. https://doi.org/10.1016/j.stem.2017.03.008 PMid:28457748
- Gómez-Lechón MJ. Oncostatin M: signal transduction and biological activity. Life Sci. 1999;65(20):2019-2030. https://doi.org/10.1016/S0024-3205(99)00296-9
- Mosley B,
De Imus C, Friend D, et al. Dual oncostatin M (OSM) receptors. Cloning
and characterization of an alternative signaling subunit conferring
OSM-specific receptor activation. J Biol Chem.
- Tanaka M, Hirabayashi Y, Sekiguchi T,
Inoue T, Katsuki M, Miyajima A. Targeted disruption of oncostatin M
receptor results in altered hematopoiesis. Blood. 2003;102(9):3154-
3162. https://doi.org/10.1182/blood-2003-02-0367 PMid:12855584
K, Takeuchi M, Hirabayashi Y, et al. Oncostatin m maintains the
hematopoietic microenvironment and retains hematopoietic progenitors in
the bone marrow. Int J Hematol. 2006;84(4):319-327.
G, Cerny-Reiterer S, Perné A, et al. Identification of oncostatin M as
a STAT5- dependent mediator of bone marrow remodeling in KIT
D816V-positive systemic mastocytosis. Am J Pathol.
- Wallace PM, MacMaster
JF, Rillema JR, Peng J, Burstein SA, Shoyab M. Thrombocytopoietic
properties of oncostatin M. Blood. 1995;86(4):1310-1315 PMid:7632937
G, Cerny-Reiterer S, Herrmann H, et al. Identification of oncostatin M
as a JAK2 V617F-dependent amplifier of cytokine production and bone
marrow remodeling in myeloproliferative neoplasms. FASEB J.
2012;26(2):894-906. https://doi.org/10.1096/fj.11-193078 PMid:22051730
K, Pietras EM, Reynaud D, et al. Myeloproliferative neoplasia remodels
the endosteal bone marrow niche into a self-reinforcing leukemic niche.
Cell Stem Cell. 2013;13(3):285-299.
- Murphy PM. Neutrophil receptors for interleukin-8 and related CXC chemokines. Semin Hematol. 1997;34(4):311-318. PMid:9347581
K, Higuchi T, Yamashita T, Koike K. Chemokine production by human
megakaryocytes derived from CD34-positive cord blood cells. Cytokine.
- Emadi S, Clay D, Desterke C, et al. IL-8
and its CXCR1 and CXCR2 receptors participate in the control of
megakaryocytic proliferation, differentiation, and ploidy in myeloid
metaplasia with myelofibrosis. Blood. 2005;105(2):464-473.m
J, Wilhelmsen L, Haraldsen G. The murine IL-8 homologues KC, MIP-2, and
LIX are found in endothelial cytoplasmic granules but not in
Weibel-Palade bodies. J Leukoc Biol. 2010;87(3):501-508.
O, Höftmann J, Theophile K, et al. Bone morphogenetic proteins are
overexpressed in the bone marrow of primary myelofibrosis and are
apparently induced by fibrogenic cytokines. Am J Pathol.
- Garimella R, Kacena MA,
Tague SE, Wang J, Horowitz MC, Anderson HC. Expression of bone
morphogenetic proteins and their receptors in the bone marrow
megakaryocytes of GATA- 1(low) mice: a possible role in osteosclerosis.
J Histochem Cytochem. 2007;55(7):745-752.
M, Xia L, Liu YC, et al. Lipocalin produced by myelofibrosis cells
affects the fate of both hematopoietic and marrow microenvironmental
cells. Blood. 2015;126(8):972-982.
- Martyré MC, Le Bousse-Kerdiles MC,
Romquin N, et al. Elevated levels of basic fibroblast growth factor in
megakaryocytes and platelets from patients with idiopathic
myelofibrosis. Br J Haematol. 1997;97(2):441-448.
L, Vener C, Savi F, et al. Increased expression of vascular endothelial
growth factor receptor 1 correlates with VEGF and microvessel density
in Philadelphia chromosome- negative myeloproliferative neoplasms. J
Clin Pathol. 2011;64(3):226-231.
S, Bianchi E, Guglielmelli P, et al. Involvement of MAF/SPP1 axis in
the development of bone marrow fibrosis in PMF patients. Leukemia.
2018;32(2):438-449. https://doi.org/10.1038/leu.2017.220 PMid:28745329
- Evrard S, Bluteau O, Tulliez M, et al.
Thrombospondin-1 is not the major activator of TGF- β1 in
thrombopoietin-induced myelofibrosis. Blood. 2011;117(1):246-249.
M, Engelhardt BM, Kröger N, et al. Thrombospondin-1 (TSP-1) in primary
myelofibrosis (PMF) - a megakaryocyte-derived biomarker which largely
discriminates PMF from essential thrombocythemia. Ann Hematol.
- Abbonante V, Di Buduo CA, Gruppi C, et
al. A new path to platelet production through matrix sensing.
Haematologica. 2017. https://doi.org/10.3324/haematol.2016.161562
- Malara A, Currao M, Gruppi C, et al.
Megakaryocytes contribute to the bone marrow-matrix environment by
expressing fibronectin, type IV collagen, and laminin. Stem Cells.
2014;32(4):926- 937. https://doi.org/10.1002/stem.1626 PMid:24357118
- Abbonante V, Di Buduo CA, Gruppi C, et
al. Thrombopoietin/TGF-β1 Loop Regulates Megakaryocyte Extracellular
Matrix Component Synthesis. Stem Cells. 2016;34(4):1123-1133.
A, Gruppi C, Rebuzzini P, et al. Megakaryocyte-matrix interaction
within bone marrow: new roles for fibronectin and factor XIII-A. Blood.
- Malara A, Gruppi C, Rebuzzini P, et al.
Megakaryocyte-matrix interaction within bone marrow: New roles for
fibronectin and factor XIII-A. Blood. 2011;117(8):2476-2483.
DF, Schad PE, Vann JM. Cross-linking of collagen and fibronectin by
factor XIIIa. Localization of participating glutaminyl residues to a
tryptic fragment of fibronectin. J Biol Chem. 1980;255(3):1181-1188.
- Abbonante V, Chitalia V, Rosti V, et al.
Upregulation of lysyl oxidase and adhesion to collagen of human
megakaryocytes and platelets in primary myelofibrosis. Blood.
2017;130(6):829- 831. https://doi.org/10.1182/blood-2017-04-777417
- Rundhaug JE. Matrix
metalloproteinases and angiogenesis. J Cell Mol Med. 2005;9(2):267-
285. https://doi.org/10.1111/j.1582-4934.2005.tb00355.x PMid:15963249
WJ, Dias S, Hattori K, et al. Stromal-derived factor 1-induced
megakaryocyte migration and platelet production is dependent on matrix
metalloproteinases. Blood. 2000;96(13):4152-4159. PMid:11110686
J, Block A, Le Bousse-Kerdilès MC, et al. Tissue inhibitors of matrix
metalloproteinases in platelets and megakaryocytes: a novel
organization for these secreted proteins. Exp Hematol.
- Wang JC. Importance of plasma matrix
metalloproteinases (MMP) and tissue inhibitors of metalloproteinase
(TIMP) in development of fibrosis in agnogenic myeloid metaplasia. Leuk
O, Neuse J, Hussein K, et al. Aberrant collagenase expression in
chronic idiopathic myelofibrosis is related to the stage of disease but
not to the JAK2 mutation status. Am J Pathol.
- Wickenhauser C, Schmitz
B, Baldus SE, et al. Selectins (CD62L, CD62P) and megakaryocytic
glycoproteins (CD41a, CD42b) mediate megakaryocyte-fibroblast
interactions in human bone marrow. Leuk Res. 2000;24(12):1013-1021.
V, Gruppi C, Catarsi P, et al. Altered fibronectin expression and
deposition by myeloproliferative neoplasm-derived mesenchymal stromal
cells. Br J Haematol. 2016;172(1):140- 144.
MA, Abbonante V, Catarsi P, et al. The spleen of patients with
myelofibrosis harbors defective mesenchymal stromal cells. Am J
Hematol. 2018. https://doi.org/10.1002/ajh.25047 PMid:29359451
RK, Ziegler S, Leisten I, et al. Activated fibronectin-secretory
phenotype of mesenchymal stromal cells in pre-fibrotic
myeloproliferative neoplasms. J Hematol Oncol. 2014;7:92.
- Cashell AW, Buss DH. The frequency and
significance of megakaryocytic emperipolesis in myeloproliferative and
reactive states. Ann Hematol. 1992;64(6):273-276.
- Schmitt A,
Drouin A, Massé JM, Guichard J, Shagraoui H, Cramer EM.
Polymorphonuclear neutrophil and megakaryocyte mutual involvement in
myelofibrosis pathogenesis. Leuk Lymphoma. 2002;43(4):719-724.
L, Di Baldassarre A, Zingariello M, et al. Increased and pathologic
emperipolesis of neutrophils within megakaryocytes associated with
marrow fibrosis in GATA- 1(low) mice. Blood. 2004;104(12):3573-3580.
E, Verrucci M, Martelli F, et al. Abnormal P-selectin localization
during megakaryocyte development determines thrombosis in the gata1low
model of myelofibrosis. Platelets. 2014;25(7):539-547.
- Spangrude GJ, Lewandowski D, Martelli
F, et al. P-Selectin Sustains Extramedullary Hematopoiesis in the Gata1
low Model of Myelofibrosis. Stem Cells. 2016;34(1):67-82.
Buduo CA, Alberelli MA, Glembostky AC, et al. Abnormal proplatelet
formation and emperipolesis in cultured human megakaryocytes from gray
platelet syndrome patients. Sci Rep. 2016;6:23213.
https://doi.org/10.1038/srep23213 PMid:26987485 PMCid:PMC4796794
S, Varshney R, Robison T, et al. Platelet TGF-β1 deficiency decreases
liver fibrosis in a mouse model of liver injury. Blood Adv.
- Kodama T, Takehara T,
Hikita H, et al. Thrombocytopenia exacerbates cholestasis-induced liver
fibrosis in mice. Gastroenterology. 2010;138(7):2487-2498,
- Meyer A, Wang W, Qu J, et al. Platelet
TGF-β1 contributions to plasma TGF-β1, cardiac fibrosis, and systolic
dysfunction in a mouse model of pressure overload. Blood.
2012;119(4):1064- 1074. https://doi.org/10.1182/blood-2011-09-377648
- Piguet PF, Vesin C.
Pulmonary platelet trapping induced by bleomycin: correlation with
fibrosis and involvement of the beta 2 integrins. Int J Exp Pathol.
1994;75(5):321-328. PMid:7528044 PMCid:PMC2001873
Y, Mishra A, Howland E, et al. Platelet-derived Wnt antagonist
Dickkopf-1 is implicated in ICAM-1/VCAM-1-mediated neutrophilic acute
lung inflammation. Blood. 2015;126(19):2220-2229.
- Rondina MT, Weyrich AS. Regulation of
the genetic code in megakaryocytes and platelets. J Thromb Haemost.
2015;13 Suppl 1:S26-32. https://doi.org/10.1111/jth.12965 PMid:26149034
- Freishtat RJ, Natale J, Benton AS, et
al. Sepsis alters the megakaryocyte-platelet transcriptional axis
resulting in granzyme B-mediated lymphotoxicity. Am J Respir Crit Care
Med. 2009;179(6):467-473. https://doi.org/10.1164/rccm.200807-1085OC
- Zaslavsky A, Baek KH,
Lynch RC, et al. Platelet-derived thrombospondin-1 is a critical
negative regulator and potential biomarker of angiogenesis. Blood.
- Wen QJ, Yang Q,
Goldenson B, et al. Targeting megakaryocytic-induced fibrosis in
myeloproliferative neoplasms by AURKA inhibition. Nat Med.
2015;21(12):1473-1480. https://doi.org/10.1038/nm.3995 PMid:26569382